Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension

BACKGROUND: Macitentan, a dual endothelin receptor antagonist (ERA), was approved in 2014 for the treatment of adults with idiopathic pulmonary arterial hypertension (PAH). Once-per-day dosing and low potential hepatic toxicity make macitentan an appealing therapeutic option for children with PAH, b...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Diagn Ther
Glavni autori: Schweintzger, Sabrina, Koestenberger, Martin, Schlagenhauf, Axel, Grangl, Gernot, Burmas, Ante, Kurath-Koller, Stefan, Pocivalnik, Mirjam, Sallmon, Hannes, Baumgartner, Daniela, Hansmann, Georg, Gamillscheg, Andreas
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
Original Article on Right Ventricular Dysfunction
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666951/
https://ncbi.nlm.nih.gov/pubmed/33224780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/cdt.2020.04.01
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items